Advances in the use of bisphosphonates in the prostate cancer setting.
Prostate cancer incidence is rising, and represents a major public health issue. Bone is by far the most common site for metastases in this disease, accounting for considerable morbidity. Until recently, there have been few viable options for the treatment of patients with hormone-refractory metastatic disease. This review examines the pathophysiology underlying the development of bone metastases. It also summarises some of the clinical approaches for the management of this common condition, focusing on recent evidence supporting the use of zoledronic acid, a member of one of the most promising groups of pharmacological agents, the third-generation bisphosphonates.
Coxon
J P
JP
Department of Urology, St George's Hospital, London, UK. jcoxon@orange.net
Oades
G M
GM
Colston
K W
KW
Kirby
R S
RS
D001859:Bone Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology*; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid